<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Drug repurposing &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/drug-repurposing/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Thu, 11 Dec 2025 02:30:05 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Drug repurposing &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>New Strategies in Cancer Cachexia Prevention Explored</title>
		<link>https://bioengineer.org/new-strategies-in-cancer-cachexia-prevention-explored/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Thu, 11 Dec 2025 02:30:00 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[cancer cachexia prevention]]></category>
		<category><![CDATA[clinical oncology]]></category>
		<category><![CDATA[Drug repurposing]]></category>
		<category><![CDATA[metronomic chemotherapy]]></category>
		<category><![CDATA[therapeutic strategies]]></category>
		<guid isPermaLink="false">https://bioengineer.org/new-strategies-in-cancer-cachexia-prevention-explored/</guid>

					<description><![CDATA[In the relentless struggle against cancer, one of the most debilitating complications that continue to perplex clinicians and researchers alike is cancer cachexia—a multifactorial syndrome characterized by severe body weight, muscle, and fat loss, dramatically impairing patient quality of life and survival outcomes. The recent review by Thakur and Chorawala, published in Medical Oncology, charts [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">305374</post-id>	</item>
		<item>
		<title>Study Finds GLP-1 Medications Significantly Reduce Mortality in Colon Cancer Patients</title>
		<link>https://bioengineer.org/study-finds-glp-1-medications-significantly-reduce-mortality-in-colon-cancer-patients/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 11 Nov 2025 13:29:54 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[cancer survival benefits]]></category>
		<category><![CDATA[colon cancer mortality]]></category>
		<category><![CDATA[Drug repurposing]]></category>
		<category><![CDATA[GLP-1 receptor agonists]]></category>
		<guid isPermaLink="false">https://bioengineer.org/study-finds-glp-1-medications-significantly-reduce-mortality-in-colon-cancer-patients/</guid>

					<description><![CDATA[A groundbreaking study conducted by researchers at the University of California San Diego has unveiled compelling evidence suggesting that glucagon-like peptide-1 (GLP-1) receptor agonists—widely recognized for their roles in managing blood glucose and facilitating weight loss—may possess potent survival benefits for patients diagnosed with colon cancer. This novel research, which harnessed real-world data from over [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">294766</post-id>	</item>
		<item>
		<title>Evaluating Costs of Repurposing Mirtazapine for Breathlessness</title>
		<link>https://bioengineer.org/evaluating-costs-of-repurposing-mirtazapine-for-breathlessness/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 04 Nov 2025 21:43:49 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[BETTER-B trial]]></category>
		<category><![CDATA[Drug repurposing]]></category>
		<category><![CDATA[economic evaluation]]></category>
		<category><![CDATA[mirtazapine]]></category>
		<category><![CDATA[severe breathlessness]]></category>
		<guid isPermaLink="false">https://bioengineer.org/evaluating-costs-of-repurposing-mirtazapine-for-breathlessness/</guid>

					<description><![CDATA[In a groundbreaking study published in BMC Health Services Research, the focus is on drug repurposing, particularly examining the economic implications of utilizing mirtazapine for severe breathlessness. The research, which forms part of the multinational BETTER-B trial, aims to address a significant gap in our understanding of how existing medications can be adapted for new [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">291518</post-id>	</item>
		<item>
		<title>Key Nervous System Components Found to Regulate Gastrointestinal Tumor Growth</title>
		<link>https://bioengineer.org/key-nervous-system-components-found-to-regulate-gastrointestinal-tumor-growth/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Fri, 24 Oct 2025 05:16:40 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[CGRP signaling]]></category>
		<category><![CDATA[Drug repurposing]]></category>
		<category><![CDATA[Gastrointestinal cancer treatment]]></category>
		<category><![CDATA[neurobiology of cancer]]></category>
		<category><![CDATA[tumor microenvironment]]></category>
		<guid isPermaLink="false">https://bioengineer.org/key-nervous-system-components-found-to-regulate-gastrointestinal-tumor-growth/</guid>

					<description><![CDATA[In a groundbreaking discovery poised to transform the landscape of gastrointestinal cancer treatment, researchers in Australia have unveiled a novel mechanism by which components of the nervous system actively promote tumor growth within the gut. This revelation centers on the role of the sensory neuropeptide Calcitonin Gene-Related Peptide (CGRP) and its co-receptor, Receptor Activity Modifying [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">286180</post-id>	</item>
		<item>
		<title>Ligand Boosts Auranofin’s Cancer Therapy Effectiveness</title>
		<link>https://bioengineer.org/ligand-boosts-auranofins-cancer-therapy-effectiveness/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sat, 09 Aug 2025 13:30:34 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Auranofin cancer therapy]]></category>
		<category><![CDATA[Drug repurposing]]></category>
		<category><![CDATA[Ligand supplementation]]></category>
		<category><![CDATA[Serum inactivation]]></category>
		<category><![CDATA[Thioredoxin reductase inhibition]]></category>
		<guid isPermaLink="false">https://bioengineer.org/ligand-boosts-auranofins-cancer-therapy-effectiveness/</guid>

					<description><![CDATA[The realm of cancer therapeutics is an ever-evolving landscape where the repurposing of existing drugs holds immense promise for accelerating treatment breakthroughs. Among such candidates, auranofin, originally developed and used for its antirheumatic properties, has surfaced as a compelling agent with anticancer potential. However, its clinical translation in oncology has encountered a significant obstacle: serum [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">254856</post-id>	</item>
		<item>
		<title>Dronedarone Suppresses Esophageal Squamous Cell Carcinoma Growth via CDK4/CDK6-RB1 Pathway: In Vitro and In Vivo Insights</title>
		<link>https://bioengineer.org/dronedarone-suppresses-esophageal-squamous-cell-carcinoma-growth-via-cdk4-cdk6-rb1-pathway-in-vitro-and-in-vivo-insights/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 07 Jan 2025 03:15:21 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[CDK4/CDK6-RB1 pathway]]></category>
		<category><![CDATA[Dronedarone]]></category>
		<category><![CDATA[Drug repurposing]]></category>
		<category><![CDATA[Esophageal squamous cell carcinoma]]></category>
		<category><![CDATA[In vitro/in vivo study]]></category>
		<guid isPermaLink="false">https://bioengineer.org/dronedarone-suppresses-esophageal-squamous-cell-carcinoma-growth-via-cdk4-cdk6-rb1-pathway-in-vitro-and-in-vivo-insights/</guid>

					<description><![CDATA[Esophageal squamous cell carcinoma (ESCC) emerges as a significant health concern worldwide, characterized by its aggressive nature and poor prognosis despite available treatment options. The pressing need for innovative therapeutic strategies drives ongoing research into potential treatments for this prevalent cancer type. In recent studies, researchers have turned their attention to repurposing existing medications, with [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">233185</post-id>	</item>
	</channel>
</rss>
